Figure 1.

Disease activity score using 28 joint counts (DAS28) at baseline and 24 weeks after rituximab application in European League Against Rheumatism (EULAR) responders and non-responders. The lines indicate the border between low disease activity (LDA), moderate disease activity (MDA), and high disease activity (HDA).